Guidelines on long-acting injectable cabotegravir for HIV prevention / World Health Organization.

Format:

Book

Author/Creator:

World Health Organization, author, issuing body.

Language:

English

Subjects (All):

HIV infections--Prevention.

HIV infections.

Physical Description:

1 online resource (x, 27 pages)

Edition:

1st ed.

Place of Publication:

Geneva : World Health Organization, 2022.

Summary:

In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing the risk of HIV acquisition. This guideline provides implementation considerations to support Member States, programme managers, policy makers, researchers, health workers, communities, and other stakeholders in the implementation of projects and programmes for CAB-LA. It also outlines critical research gaps for CAB-LA.

Contents:

Acknowledgements V

Abbreviations and acronyms vii

Definitions of key terms viii

Executive summary IX

Purpose ix

Guideline development methodology ix

New recommendation X

Implications for implementation X

1. Introduction 1

1.1 Background 1

1.2 Objective and intended audience 2

1.3 Guiding principles 3

2. Methods for guideline development 4

3. Rationale and supporting evidence 5

3.1 Summary of review findings 5

3.2 Cost-eflectiveness 8

3.3 Values and preferences 9

3.4 Feasibility 10

3.5 Equity 10

3.6 Rationale or recommendation 10

4. Implementation considerations 12

4.1 HIV testing and other testing requirements 12

4.2 Service delivery 14

4.3 Comprehensive services IS

4.4 Offering a choice of PrEP options 15

4.5 Involving communities 15

4.6 Creating awareness and demand 15

4.7 Adherence support and discontinuation 16

4.8 Training and support for providers 16

5. Research gaps and needs '7

5.1 Providing CAB-LA for key populations 17

5.2 CAB-LA for adolescents under age 18 17

5.3 Safety in pregnancy and breastfeeding 18

5.4 Optimal HIV testing strategies and drug resistance 18

5.5 Service delivery models •9

5.6 Population-level impact and costs and cost-effectiveness 20

6. Updating and dissemination 21

References 11

Annex. Process for developing the guidelines 25

Web Annexes

Web Annex A. Declarations of interest for the Guideline Development Group and external peer reviewers

Web Annex B. Systematic review, meta-analysis and GRADE evidence profile on safety, efficacy, and effectiveness of long-acting injectable cabotegravir (CAB-LA) as pte-exposurt prophylaxis (PrEP) to reduce the risk of HIV acquisition

Web Annex C. Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis, including long-acting injectable cabotegravir. to prevent HIV infection

Web Annex D. Projected population impact of expanding PrEP coverage by offering long-acting injectable PrEP in different settings: model comparison analysis

Web Annex E. Predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study

Web Annex F. Perspectives and preferences regarding long-acting injectable cabotegravir for HIV prevention among pre-exposure prophylaxis (PrEP) providers: a global survey and in-depth interviews

Web Annex G. Evidence-to-decision making table.

Notes:

Description based on online resource; title from PDF title page (World Health Organization, viewed April 22, 2023).